Sachin Kalyani, MD
Ophthalmology · Hanover, MDNPI 1538283486
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,645 of the $61,308 with a category attached, or 63.0%. 21 manufacturers reported payments, led by Oyster Point Pharma, Inc. at 36.0% of the total. Reporting peaked in 2019 at $22,147 and has fallen 66.6% since, to $7,404 in 2025. Among ophthalmology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $388.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Oyster Point Pharma, Inc.$22K
- Novartis$13K
- Biotissue Holdings Inc.$10K
- Shire North American Group Inc$8K
- Tarsus Pharmaceuticals, Inc.$5K
- Lensar, Inc.$428
- plus $2K from 15 others
What the payments were for
- Consulting fees$9,69516%
- Speaking & faculty fees$38,64563%
- Travel & lodging$7,09812%
- Food & beverage$5,85010%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Oyster Point Pharma, Inc. | 30 | $22,101 |
| Novartis | 16 | $13,356 |
| Biotissue Holdings Inc. | 24 | $9,729 |
| Shire North American Group Inc | 10 | $8,481 |
| Tarsus Pharmaceuticals, Inc. | 17 | $5,393 |
| Lensar, Inc. | 1 | $428 |
| Bausch & Lomb Americas Inc. | 11 | $360 |
| AbbVie(2 entities) | 7 | $300 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $211 |
| Alcon | 5 | $188 |
| Sun Pharmaceutical Industries Inc. | 9 | $180 |
| Dompe US, Inc. | 4 | $119 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $98 |
| Kala Pharmaceuticals, Inc. | 5 | $83 |
| Harrow Eye, LLC | 2 | $61 |
| Rayner Intraocular Lenses Limited | 2 | $60 |
| Amgen | 2 | $57 |
| Rxsight Inc | 2 | $45 |
| Ocular Therapeutix, Inc. | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Eyepoint US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYRVAYA$21,726
- XIIDRA$21,335
- AmnioGraft$4,587
- Prokera$2,087
- LENSAR LASER SYSTEM$428
- XDEMVY$235
- VUITY$120
- TRYPTYR$110
- PROLENSA$104
- LOTEMAX SM$104
How this compares
$61,308 in reported general payments places this provider in the 90th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 47 | $60,210 |
| Cyclosporine | 35 | $12,455 |
| Prednisolone Acetate | 81 | $2,564 |
| Travoprost | 12 | $2,467 |
| Latanoprost | 143 | $1,984 |
| Fluorometholone | 21 | $1,376 |
| ValacyclovirValacyclovir Hcl | 27 | $1,294 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 40 | $783 |
| Timolol Maleate | 52 | $680 |
| Acyclovir | 14 | $401 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 23 | $278 |
| Ofloxacin | 17 | $202 |
| Azelastine Hcl | 15 | $152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $300 | $60,21047 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 493 ophthalmology providers in Maryland.
Other ophthalmology in Hanover
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$782K
- Lisa FeulnerBel Air$434K
- Allen HuHagerstown$379K
- Susan BresslerLutherville$341K
- Renee BovelleGlenn Dale$292K
- Neil BresslerBaltimore$265K
- Scott LaborwitTowson$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.